Patents Assigned to Intellikine, Inc.
  • MTOR modulators and uses thereof
    Patent number: 9629843
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 25, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, INTELLIKINE, INC.
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes
  • Heterocyclic compounds and uses thereof
    Patent number: 9085560
    Abstract: A method of inhibiting phosphatidyl inositol-3 kinase (PI3 kinase), comprising: contacting the PI3 kinase with an effective amount of a compound or pharmaceutically acceptable salt of the formula below, wherein the variables R1, R2, W1, W2, W3, W4, W5, are W6 are defined herein.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: July 21, 2015
    Assignee: INTELLIKINE, INC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Kinase inhibitors and methods of use
    Patent number: 8637542
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PB kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 28, 2014
    Assignee: Intellikine, Inc.
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Substituted isoquinolin-1(2H)-ones, and methods of use thereof
    Patent number: 8193182
    Abstract: Chemical entities of Formula I: that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: June 5, 2012
    Assignee: Intellikine, Inc.
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20110281866
    Abstract: The present invention provides heterocyclic compounds for use as kinase inhibitors and in other applications. Also provided are pharmaceutical compositions and methods of treatments of diseases and conditions associated with P13 kinase activity.
    Type: Application
    Filed: September 28, 2009
    Publication date: November 17, 2011
    Applicant: INTELLIKINE, INC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
    Publication number: 20110269779
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Application
    Filed: November 17, 2009
    Publication date: November 3, 2011
    Applicant: INTELLIKINE, INC.
    Inventors: Troy Edward Wilson, Christian Rommel, Yi Liu, Pingda Ren
  • MTOR Modulators and Uses Thereof
    Publication number: 20110224223
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Application
    Filed: July 8, 2009
    Publication date: September 15, 2011
    Applicants: The Regents of the University of California, a California corporation, Intellikine, Inc.
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes